IL1B and Alzheimer disease: It is not known whether increased IL-1β and microglial toxicity as a result of this positive feedback loop might precede Aβ production and plaque formation over the time span of AD pathogenesis and more research should be conducted about the relationship between IL-1β and AD, as IL-1β could be an AD drug target, IL-1β is already a drug target for autoimmune disorders [69].